Literature DB >> 16932506

Drug Insight: using statins to treat neuroinflammatory disease.

Martin S Weber1, Thomas Prod'homme, Lawrence Steinman, Scott S Zamvil.   

Abstract

Statins, a family of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are used primarily to reduce atherogenesis and cardiovascular morbidity. Surprisingly, they have also been shown to have immunomodulatory properties that might be of benefit for the treatment of autoimmune disorders. Statins can prevent and even reverse ongoing paralysis in experimental autoimmune encephalomyelitis--the mouse model for multiple sclerosis--and on the basis of these findings, statins are now being tested in patients with multiple sclerosis in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16932506     DOI: 10.1038/ncpneuro0047

Source DB:  PubMed          Journal:  Nat Clin Pract Neurol        ISSN: 1745-834X


  9 in total

1.  HMG-CoA Reductase Inhibitors Bind to PPARα to Upregulate Neurotrophin Expression in the Brain and Improve Memory in Mice.

Authors:  Avik Roy; Malabendu Jana; Madhuchhanda Kundu; Grant T Corbett; Suresh B Rangaswamy; Rama K Mishra; Chi-Hao Luan; Frank J Gonzalez; Kalipada Pahan
Journal:  Cell Metab       Date:  2015-06-25       Impact factor: 27.287

Review 2.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

3.  Simvastatin induces cell death in a mouse cerebellar slice culture (CSC) model of developmental myelination.

Authors:  Zhongmin Xiang; Steven A Reeves
Journal:  Exp Neurol       Date:  2008-09-27       Impact factor: 5.330

Review 4.  The Use of Oral Disease-Modifying Therapies in Multiple Sclerosis.

Authors:  Benedikt Kretzschmar; Hannah Pellkofer; Martin S Weber
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

Review 5.  Neuropsychiatric manifestations of depression in multiple sclerosis: neuroinflammatory, neuroendocrine, and neurotrophic mechanisms in the pathogenesis of immune-mediated depression.

Authors:  Michele L Pucak; Katherine A L Carroll; Douglas A Kerr; Adam I Kaplin
Journal:  Dialogues Clin Neurosci       Date:  2007       Impact factor: 5.986

6.  Effect of beta-blocker therapy on the risk of infections and death after acute stroke--a historical cohort study.

Authors:  Ilko L Maier; André Karch; Rafael Mikolajczyk; Mathias Bähr; Jan Liman
Journal:  PLoS One       Date:  2015-02-02       Impact factor: 3.240

Review 7.  Systemic Response to Infection Induces Long-Term Cognitive Decline: Neuroinflammation and Oxidative Stress as Therapeutical Targets.

Authors:  Patricia Alves Reis; Hugo Caire Castro-Faria-Neto
Journal:  Front Neurosci       Date:  2022-02-18       Impact factor: 4.677

Review 8.  Multiple sclerosis therapy: an update on recently finished trials.

Authors:  Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd Kieseier; Heinz Wiendl
Journal:  J Neurol       Date:  2007-11-15       Impact factor: 6.682

9.  Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Sawsan Youssef; Shannon E Dunn; Lawrence Steinman; Scott S Zamvil
Journal:  J Neuroinflammation       Date:  2014-02-06       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.